tiprankstipranks
Trending News
More News >

Biocon Pharma Gains US FDA Approval for Everolimus Tablets

Story Highlights
Biocon Pharma Gains US FDA Approval for Everolimus Tablets

Confident Investing Starts Here:

Biocon Limited ( (IN:BIOCON) ) just unveiled an update.

Biocon Limited announced that its subsidiary, Biocon Pharma Limited, has received approval from the US FDA for its ANDA for Everolimus Tablets, which are used in organ transplantation. This approval enhances Biocon’s portfolio of complex drug products, potentially strengthening its market position and offering new opportunities for growth.

More about Biocon Limited

Biocon Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of complex drug products. The company is known for its vertically integrated approach and serves markets with a focus on prescription medications.

YTD Price Performance: -17.25%

Average Trading Volume: 164,169

Current Market Cap: 366.4B INR

See more data about BIOCON stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App